Multinational biopharmaceutical company Polaris Group announced their application for a rolling submission of a new mesothelioma treatment this month. The Biologic License Application…
Results of a new phase 3 clinical trial published in the Journal of Clinical Oncology indicate that a chemoimmunotherapy regimen combining chemotherapy with immunotherapy…
Asbestos is widely known as an occupational hazard, but emerging evidence suggests that prolonged exposure to environmental asbestos could lead to severe autoimmune…
A novel therapy for mesothelioma has been given orphan drug designation by the U.S. Food and Drug Administration. Avenge Bio, a biotechnology company working…
Researchers from the University of Pennsylvania’s Department of Earth and Environmental Science have found that bacteria from extreme marine environments may potentially detoxify asbestos.
Pharmaceutical company Merck says use of its immunotherapy drug Keytruda in conjunction with chemotherapy increases the survival rate for people with advanced pleural…
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
Reviewed & Fact-Checked
This page was reviewed by:
Fact-checked and verified content:
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Please read our editorial guidelines to learn more about our content creation and review process.
